UK medical research charity LifeArc and US non-profit, multispecialty academic medical center Cleveland Clinic have signed a new 10-year master services agreement (MSA) for the development of monoclonal antibody-based therapeutics.
LifeArc will provide expertise in humanization of monoclonal antibodies (MAbs) to target key drivers of conditions identified by Cleveland Clinic, including cancer and complement-mediated diseases.
This MSA builds on a successful track record of the two organizations working together since 2019 on four humanization projects, with a fifth project for 2025 already underway.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze